| 1 |
González-moreno L, Santamaría-cano A, Paradela A, Martínez-chantar ML, Martín MÁ, Pérez-carreras M, García-picazo A, Vázquez J, Calvo E, González-aseguinolaza G, Saheki T, del Arco A, Satrústegui J, Contreras L. Exogenous aralar/slc25a12 can replace citrin/slc25a13 as malate aspartate shuttle component in liver. Molecular Genetics and Metabolism Reports 2023;35:100967. [DOI: 10.1016/j.ymgmr.2023.100967] [Reference Citation Analysis]
|
| 2 |
Berasain C, Arechederra M, Argemí J, Fernández-Barrena MG, Avila MA. Loss of liver function in chronic liver disease: An identity crisis. J Hepatol 2023;78:401-14. [PMID: 36115636 DOI: 10.1016/j.jhep.2022.09.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 3 |
Son S, Lee K. Development of mRNA Vaccines/Therapeutics and Their Delivery System. Mol Cells 2023;46:41-7. [PMID: 36697236 DOI: 10.14348/molcells.2023.2165] [Reference Citation Analysis]
|
| 4 |
Li D, Liu Q, Yang M, Xu H, Zhu M, Zhang Y, Xu J, Tian C, Yao J, Wang L, Liang Y. Nanomaterials for mRNA ‐based Therapeutics: Challenges and Opportunities. Bioengineering & Transla Med 2023. [DOI: 10.1002/btm2.10492] [Reference Citation Analysis]
|
| 5 |
Miliotou AN, Foltopoulou PF, Ingendoh-Tsakmakidis A, Tsiftsoglou AS, Vizirianakis IS, Pappas IS, Papadopoulou LC. Protein Transduction Domain-Mediated Delivery of Recombinant Proteins and In Vitro Transcribed mRNAs for Protein Replacement Therapy of Human Severe Genetic Mitochondrial Disorders: The Case of Sco2 Deficiency. Pharmaceutics 2023;15. [PMID: 36678915 DOI: 10.3390/pharmaceutics15010286] [Reference Citation Analysis]
|
| 6 |
Vavilis T, Stamoula E, Ainatzoglou A, Sachinidis A, Lamprinou M, Dardalas I, Vizirianakis IS. mRNA in the Context of Protein Replacement Therapy. Pharmaceutics 2023;15. [PMID: 36678793 DOI: 10.3390/pharmaceutics15010166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Zhao XJ, Mohsen AW, Mihalik S, Solo K, Aliu E, Shi H, Basu S, Kochersperger C, Van't Land C, Karunanidhi A, Coughlan KA, Siddiqui S, Rice LM, Hillier S, Guadagnin E, Giangrande PH, Martini PGV, Vockley J. Synthetic mRNA rescues very long-chain acyl-CoA dehydrogenase deficiency in patient fibroblasts and a murine model. Mol Genet Metab 2023;138:106982. [PMID: 36580829 DOI: 10.1016/j.ymgme.2022.106982] [Reference Citation Analysis]
|
| 8 |
Nakayama H, Nobe Y, Koike M, Taoka M. Liquid Chromatography-Mass Spectrometry-Based Qualitative Profiling of mRNA Therapeutic Reagents Using Stable Isotope-Labeled Standards Followed by the Automatic Quantitation Software Ariadne. Anal Chem 2023;95:1366-75. [PMID: 36574727 DOI: 10.1021/acs.analchem.2c04323] [Reference Citation Analysis]
|
| 9 |
Alvarez D, Masse-ranson G, Sedimbi SK, Wisti P, Rodriguez L, Santana J, Manning T, Towner T, Geilich B, Mihai C, Mishra A, Gurumurthy S, Frederick J, von Andrian UH, Hoggatt J, Moore MJ, Mora JR. Functional mRNA delivery to hematopoietic stem and progenitor cellsin vivo.. [DOI: 10.1101/2022.12.15.520650] [Reference Citation Analysis]
|
| 10 |
Jericó D, Córdoba KM, Sampedro A, Jiang L, Joucla G, Cabanne C, Lanciego JL, Martini PGV, Berraondo P, Ávila MA, Fontanellas A. Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment. Life (Basel) 2022;12. [PMID: 36430993 DOI: 10.3390/life12111858] [Reference Citation Analysis]
|
| 11 |
Mei R, Wan Z, Li Z, Wei M, Qin W, Yuan L, Liu L, Yang G. “All-in-One” Exosome Engineering Strategy for Effective Therapy of Familial Hypercholesterolemia. ACS Appl Mater Interfaces 2022. [DOI: 10.1021/acsami.2c15785] [Reference Citation Analysis]
|
| 12 |
Gurung S, Timmermand OV, Perocheau D, Gil-martinez AL, Minnion M, Touramanidou L, Fang S, Messina M, Khalil Y, Barber AR, Edwards RS, Finn PF, Cavedon A, Siddiqui S, Rice L, Martini PG, Mills PB, Waddington SN, Gissen P, Eaton S, Ryten M, Feelisch M, Frassetto A, Witney TH, Baruteau J. mRNA therapy restores ureagenesis and corrects glutathione metabolism in argininosuccinic aciduria.. [DOI: 10.1101/2022.10.19.512931] [Reference Citation Analysis]
|
| 13 |
Zhang J, Zhang T, Gao J. Biocompatible Iron Oxide Nanoparticles for Targeted Cancer Gene Therapy: A Review. Nanomaterials 2022;12:3323. [DOI: 10.3390/nano12193323] [Reference Citation Analysis]
|
| 14 |
Osouli-bostanabad K, Puliga S, Serrano DR, Bucchi A, Halbert G, Lalatsa A. Microfluidic Manufacture of Lipid-Based Nanomedicines. Pharmaceutics 2022;14:1940. [DOI: 10.3390/pharmaceutics14091940] [Reference Citation Analysis]
|
| 15 |
Zabaleta N, Torella L, Weber ND, Gonzalez-Aseguinolaza G. mRNA and gene editing: Late breaking therapies in liver diseases. Hepatology 2022;76:869-87. [PMID: 35243655 DOI: 10.1002/hep.32441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 16 |
Waheed S, Li Z, Zhang F, Chiarini A, Armato U, Wu J. Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery. J Nanobiotechnology 2022;20:395. [PMID: 36045386 DOI: 10.1186/s12951-022-01605-4] [Reference Citation Analysis]
|
| 17 |
Cao Y, He Z, Chen Q, He X, Su L, Yu W, Zhang M, Yang H, Huang X, Li J. Helper-Polymer Based Five-Element Nanoparticles (FNPs) for Lung-Specific mRNA Delivery with Long-Term Stability after Lyophilization. Nano Lett 2022. [PMID: 35969167 DOI: 10.1021/acs.nanolett.2c01784] [Reference Citation Analysis]
|
| 18 |
Martinez-Pizarro A, Desviat LR. RNA solutions to treat inborn errors of metabolism. Mol Genet Metab 2022;136:289-95. [PMID: 35849888 DOI: 10.1016/j.ymgme.2022.07.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 19 |
Qin S, Tang X, Chen Y, Chen K, Fan N, Xiao W, Zheng Q, Li G, Teng Y, Wu M, Song X. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Target Ther 2022;7:166. [PMID: 35597779 DOI: 10.1038/s41392-022-01007-w] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 32.0] [Reference Citation Analysis]
|
| 20 |
Prakash G, Shokr A, Willemen N, Bashir SM, Shin SR, Hassan S. Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids. Adv Drug Deliv Rev 2022;184:114197. [PMID: 35288219 DOI: 10.1016/j.addr.2022.114197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 21 |
Longo M, Paolini E, Meroni M, Dongiovanni P. Cutting-Edge Therapies and Novel Strategies for Acute Intermittent Porphyria: Step-by-Step towards the Solution. Biomedicines 2022;10:648. [DOI: 10.3390/biomedicines10030648] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 22 |
Taina-González L, de la Fuente M. The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA. Pharmaceutics 2022;14:460. [PMID: 35214191 DOI: 10.3390/pharmaceutics14020460] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 23 |
Tarab-Ravski D, Stotsky-Oterin L, Peer D. Delivery strategies of RNA therapeutics to leukocytes. J Control Release 2022:S0168-3659(22)00030-X. [PMID: 35041904 DOI: 10.1016/j.jconrel.2022.01.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 24 |
Lee M, Lee I, Wang K. Recent Advances in RNA Therapy and Its Carriers to Treat the Single-Gene Neurological Disorders. Biomedicines 2022;10:158. [DOI: 10.3390/biomedicines10010158] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 25 |
Córdoba KM, Jericó D, Sampedro A, Jiang L, Iraburu MJ, Martini PG, Berraondo P, Avila MA, Fontanellas A. Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases. mRNA-Based Therapeutics 2022. [DOI: 10.1016/bs.ircmb.2022.03.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 26 |
Gill K, Minall L, Rodriguez Nassif A. pDNA and mRNA vaccines. Practical Aspects of Vaccine Development 2022. [DOI: 10.1016/b978-0-12-814357-5.00007-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 27 |
Di Trani CA, Cirella A, Arrizabalaga L, Fernandez-sendin M, Bella A, Aranda F, Melero I, Berraondo P. Overcoming the limitations of cytokines to improve cancer therapy. International Review of Cell and Molecular Biology 2022. [DOI: 10.1016/bs.ircmb.2022.05.002] [Reference Citation Analysis]
|
| 28 |
Yang T, Poenisch M, Khanal R, Hu Q, Dai Z, Li R, Song G, Yuan Q, Yao Q, Shen X, Taubert R, Engel B, Jaeckel E, Vogel A, Falk CS, Schambach A, Gerovska D, Araúzo-Bravo MJ, Vondran FWR, Cantz T, Horscroft N, Balakrishnan A, Chevessier F, Ott M, Sharma AD. Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model. J Hepatol 2021;75:1420-33. [PMID: 34453962 DOI: 10.1016/j.jhep.2021.08.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 29 |
Li J, Men K, Gao Y, Wu J, Lei S, Yang Y, Pan H. Single Micelle Vectors based on Lipid/Block Copolymer Compositions as mRNA Formulations for Efficient Cancer Immunogene Therapy. Mol Pharm 2021;18:4029-45. [PMID: 34559545 DOI: 10.1021/acs.molpharmaceut.1c00461] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 30 |
Di Trani CA, Fernandez-Sendin M, Cirella A, Segués A, Olivera I, Bolaños E, Melero I, Berraondo P. Advances in mRNA-based drug discovery in cancer immunotherapy. Expert Opin Drug Discov 2021;:1-13. [PMID: 34496689 DOI: 10.1080/17460441.2021.1978972] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 31 |
Wu L, Zhou W, Lin L, Chen A, Feng J, Qu X, Zhang H, Yue J. Delivery of therapeutic oligonucleotides in nanoscale. Bioact Mater 2022;7:292-323. [PMID: 34466734 DOI: 10.1016/j.bioactmat.2021.05.038] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 32 |
Wang C, Liu Y, Zhang X, Wang H, Cui Y, Zhi X, Zheng J, Wang N, Shu J, Li D, Cai C. Phenotypic and genotypic analysis of children with methylmalonic academia: A single-center study in China and a recent literature review. Clin Chim Acta 2021;522:14-22. [PMID: 34389282 DOI: 10.1016/j.cca.2021.08.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 33 |
Fang C, Li Y, Hu S, Wang H, Chen X, Zhu X. Self-Assembled Growing DNA Tree Mediated by Exosomes for Amplified Imaging of Messenger RNA in Living Cells. Anal Chem 2021;93:8414-22. [PMID: 34114453 DOI: 10.1021/acs.analchem.1c00211] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 34 |
Cao J, Choi M, Guadagnin E, Soty M, Silva M, Verzieux V, Weisser E, Markel A, Zhuo J, Liang S, Yin L, Frassetto A, Graham AR, Burke K, Ketova T, Mihai C, Zalinger Z, Levy B, Besin G, Wolfrom M, Tran B, Tunkey C, Owen E, Sarkis J, Dousis A, Presnyak V, Pepin C, Zheng W, Ci L, Hard M, Miracco E, Rice L, Nguyen V, Zimmer M, Rajarajacholan U, Finn PF, Mithieux G, Rajas F, Martini PGV, Giangrande PH. mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease. Nat Commun 2021;12:3090. [PMID: 34035281 DOI: 10.1038/s41467-021-23318-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 35 |
Delnoy B, Coelho AI, Rubio-Gozalbo ME. Current and Future Treatments for Classic Galactosemia. J Pers Med 2021;11:75. [PMID: 33525536 DOI: 10.3390/jpm11020075] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 36 |
Legere RM, Cohen ND, Poveda C, Bray JM, Barhoumi R, Szule JA, de la Concha-Bermejillo A, Bordin AI, Pollet J. Safe and effective aerosolization of in vitro transcribed mRNA to the respiratory tract epithelium of horses without a transfection agent. Sci Rep 2021;11:371. [PMID: 33432084 DOI: 10.1038/s41598-020-79855-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 37 |
Cozmescu AC, Counsell J, Gissen P. Gene therapies targeting the liver. J Hepatol 2021;74:235-6. [PMID: 33071009 DOI: 10.1016/j.jhep.2020.08.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 38 |
Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 2021;20:101-24. [PMID: 33277608 DOI: 10.1038/s41573-020-0090-8] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 1167] [Article Influence: 358.7] [Reference Citation Analysis]
|
| 39 |
Zhao L, Wang X, Zhang X, Liu X, Ma N, Zhang Y, Zhang S. Therapeutic strategies for acute intermittent porphyria. Intractable Rare Dis Res 2020;9:205-16. [PMID: 33139979 DOI: 10.5582/irdr.2020.03089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 40 |
Jiang L, Park JS, Yin L, Laureano R, Jacquinet E, Yang J, Liang S, Frassetto A, Zhuo J, Yan X, Zhu X, Fortucci S, Hoar K, Mihai C, Tunkey C, Presnyak V, Benenato KE, Lukacs CM, Martini PGV, Guey LT. Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia. Nat Commun 2020;11:5339. [PMID: 33087718 DOI: 10.1038/s41467-020-19156-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 41 |
Tossberg JT, Esmond TM, Aune TM. A simplified method to produce mRNAs and functional proteins from synthetic double-stranded DNA templates. Biotechniques 2020;69:281-8. [PMID: 32815735 DOI: 10.2144/btn-2020-0037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 42 |
Nelson J, Sorensen EW, Mintri S, Rabideau AE, Zheng W, Besin G, Khatwani N, Su SV, Miracco EJ, Issa WJ, Hoge S, Stanton MG, Joyal JL. Impact of mRNA chemistry and manufacturing process on innate immune activation. Sci Adv 2020;6:eaaz6893. [PMID: 32637598 DOI: 10.1126/sciadv.aaz6893] [Cited by in Crossref: 94] [Cited by in F6Publishing: 96] [Article Influence: 31.3] [Reference Citation Analysis]
|
| 43 |
Veiga N, Diesendruck Y, Peer D. Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes. Adv Drug Deliv Rev 2020;159:364-76. [PMID: 32298783 DOI: 10.1016/j.addr.2020.04.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 44 |
Gómez-Aguado I, Rodríguez-Castejón J, Vicente-Pascual M, Rodríguez-Gascón A, Solinís MÁ, Del Pozo-Rodríguez A. Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives. Nanomaterials (Basel) 2020;10:E364. [PMID: 32093140 DOI: 10.3390/nano10020364] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 26.3] [Reference Citation Analysis]
|
| 45 |
Kamimura K, Yokoo T, Abe H, Terai S. Gene Therapy for Liver Cancers: Current Status from Basic to Clinics. Cancers (Basel) 2019;11:E1865. [PMID: 31769427 DOI: 10.3390/cancers11121865] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 46 |
Tang X, Zhang S, Fu R, Zhang L, Huang K, Peng H, Dai L, Chen Q. Therapeutic Prospects of mRNA-Based Gene Therapy for Glioblastoma. Front Oncol 2019;9:1208. [PMID: 31781503 DOI: 10.3389/fonc.2019.01208] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 47 |
Silva CD, Mateus JE, Teles C, Vaio T. Acute intermittent porphyria: analgesia can be dangerous. BMJ Case Rep 2019;12:e231133. [PMID: 31570358 DOI: 10.1136/bcr-2019-231133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 48 |
Jauze L, Monteillet L, Mithieux G, Rajas F, Ronzitti G. Challenges of Gene Therapy for the Treatment of Glycogen Storage Diseases Type I and Type III. Hum Gene Ther 2019;30:1263-73. [PMID: 31319709 DOI: 10.1089/hum.2019.102] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 49 |
Fontanellas A, Ávila MA, Anderson KE, Deybach JC. Current and innovative emerging therapies for porphyrias with hepatic involvement. J Hepatol 2019;71:422-33. [PMID: 31102718 DOI: 10.1016/j.jhep.2019.05.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 50 |
Ferreira GC, Oberstaller J, Fonseca R, Keller TE, Adapa SR, Gibbons J, Wang C, Liu X, Li C, Pham M, Dayhoff Ii GW, Duong LM, Reyes LT, Laratelli LE, Franz D, Fatumo S, Bari AG, Freischel A, Fiedler L, Dokur O, Sharma K, Cragun D, Busby B, Jiang RHY. Iron Hack - A symposium/hackathon focused on porphyrias, Friedreich's ataxia, and other rare iron-related diseases. F1000Res 2019;8:1135. [PMID: 31824661 DOI: 10.12688/f1000research.19140.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 51 |
Martini PGV, Guey LT. A New Era for Rare Genetic Diseases: Messenger RNA Therapy. Hum Gene Ther 2019;30:1180-9. [PMID: 31179759 DOI: 10.1089/hum.2019.090] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
|
